Literature DB >> 12177257

A prospective, randomized study of preoperative autologous donation for hip replacement surgery.

Dinna B Billote1, Silas N Glisson, David Green, Richard L Wixson.   

Abstract

BACKGROUND: Preoperative autologous blood donation is commonly performed to meet potential perioperative transfusion needs and is a common practice prior to total hip arthroplasty. Using standardized transfusion guidelines, we prospectively analyzed the effectiveness of preoperative autologous donation as a method for decreasing allogeneic transfusion among patients undergoing unilateral primary total hip replacement who were eligible to donate autologous blood.
METHODS: Patients who were scheduled for primary total hip replacement surgery and who had a preoperative baseline hemoglobin level >or=120 g/L were randomized either to donate two units of blood (autologous donors) or not to donate any blood (nondonors). The donors and nondonors were compared with regard to demographic data, blood-loss volumes, hemoglobin measurements, and transfusion rates. Randomization continued until data were obtained from at least forty patients per treatment group.
RESULTS: Of the ninety-six patients who completed the study, forty-two were autologous donors and fifty-four were nondonors. There were no significant differences between the donors and nondonors with regard to age, male:female ratio, estimated blood volume, baseline physical condition, or operative blood loss. The hemoglobin values at the time of enrollment (baseline), at the time of hospital discharge, and six weeks postoperatively were not significantly different between the two groups, although values at the time of admission (129 +/- 13 g/L versus 138 +/- 12 g/L) and in the recovery room (104 +/- 12 g/L versus 115 +/- 13 g/L) were significantly lower in the autologous donor group (p < 0.05). No patient in either group required an allogeneic transfusion. Twenty-nine (69%) of the forty-two donors received an autologous transfusion. Thirty-four (41%) of eighty-two autologous units were wasted. At a charge of $379 per autologous unit, there was an additional cost of $758 for each patient in the donor group.
CONCLUSIONS: Preoperative autologous donation provided no benefit for nonanemic patients undergoing primary total hip replacement surgery. Preoperative autologous donation increased the likelihood of autologous transfusion, wastage of predonated units, and costs.

Entities:  

Mesh:

Year:  2002        PMID: 12177257     DOI: 10.2106/00004623-200208000-00002

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  20 in total

1.  Postoperative high-dose intravenous iron sucrose with low dose erythropoietin therapy after total hip replacement.

Authors:  Jiyeol Yoon; Sungmin Kim; Soo Chan Lee; Hongsub Lim
Journal:  Korean J Intern Med       Date:  2010-11-27       Impact factor: 2.884

2.  Minorities are less likely to receive autologous blood transfusion for major elective orthopaedic surgery.

Authors:  Mariano E Menendez; David Ring
Journal:  Clin Orthop Relat Res       Date:  2014-07-16       Impact factor: 4.176

3.  10 Autologous Hemotherapy.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

4.  Recommendations for the transfusion management of patients in the peri-operative period. I. The pre-operative period.

Authors:  Giancarlo Maria Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2011-01       Impact factor: 3.443

5.  CORR Insights®: minorities are less likely to receive autologous blood transfusion for major elective orthopaedic surgery.

Authors:  M J Grecula
Journal:  Clin Orthop Relat Res       Date:  2014-08-15       Impact factor: 4.176

6.  Predicting lowest hemoglobin level and risk of blood transfusion in spinal fusion surgery for adolescent idiopathic scoliosis.

Authors:  Hany Abdel Gawwad Soliman; Marie Beausejour; Julie Joncas; Marjolaine Roy-Beaudry; Soraya Barchi; Jean-Marc Mac-Thiong; Hubert Labelle; Guy Grimard; Stefan Parent
Journal:  Eur Spine J       Date:  2019-03-08       Impact factor: 3.134

7.  Tranexamic acid reduces allogenic transfusion in revision hip arthroplasty.

Authors:  Shahryar Noordin; Terrence S Waters; Donald S Garbuz; Clive P Duncan; Bassam A Masri
Journal:  Clin Orthop Relat Res       Date:  2011-02       Impact factor: 4.176

8.  Topical tranexamic acid reduces blood loss and transfusion rates associated with primary total hip arthroplasty.

Authors:  Chih-Hsiang Chang; Yuhan Chang; Dave W Chen; Steve W N Ueng; Mel S Lee
Journal:  Clin Orthop Relat Res       Date:  2014-01-03       Impact factor: 4.176

Review 9.  Total joint replacement and blood loss: what is the best equation?

Authors:  Emmanuel Gibon; Jean-Pierre Courpied; Moussa Hamadouche
Journal:  Int Orthop       Date:  2013-02-06       Impact factor: 3.075

10.  Nonanemic patients do not benefit from autologous blood donation before total hip replacement.

Authors:  Friedrich Boettner; Eric I Altneu; Brendan A Williams; Matthew Hepinstall; Thomas P Sculco
Journal:  HSS J       Date:  2009-12-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.